Residual Host Cell Protein (HCP)

Residual Host Cell Protein (HCP) refers to process-related protein impurities originating from the host cells used to express recombinant biologics, remaining in the final drug substance or drug product at low levels after purification. Host systems such as Chinese hamster ovary cells, E. coli, or yeast produce numerous endogenous proteins that can co-purify with the therapeutic molecule, and while purification removes the vast majority, trace HCPs may persist and must be controlled due to potential immunogenicity, impact on stability, or interference with product potency.

The biopharmaceutical industry monitors HCPs as critical quality attributes, using validated assays such as ELISA designed for broad detection of host proteins, complemented by mass spectrometry for identification of specific problematic impurities. HCP risk is influenced by cell line characteristics, culture conditions, downstream purification design, and product-specific binding behaviours. Certain HCPs can be high-risk if they are enzymatically active, bind to the drug molecule, or resist purification, potentially contributing to degradation or immune reactions. Regulatory agencies expect robust HCP control strategies including process validation, impurity trend monitoring, and specification justification based on clinical and manufacturing data. As biologic modalities expand and purification processes become more complex, controlling residual host cell proteins remains essential for ensuring consistent product quality, patient safety, and regulatory compliance.